NCT00399113View on ClinicalTrials.gov

Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2008

Conditions
Metastatic Melanoma
Interventions
DRUG

188Re-PTI-6D2

monoclonal antibody

Trial Locations (2)

52621

Chaim Sheba Medical Center, Tel Litwinsky

91120

Hadassah Hebrew University Hospital, Jerusalem

Sponsors

Lead Sponsor

Pain Therapeutics
All Listed Sponsors
lead

Pain Therapeutics

INDUSTRY

NCT00399113 - Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter